The DIDB Concomitant Meds Navigator has been updated in January 2026 and is available in the Tools.
This update includes characterization of 54 compounds, encompassing substrates of CYP2D6, CYP3A, UGTs, OATP1B1, and OATP1B3 (N = 10); inhibitors of CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A, UGTs, P-gp, BCRP, OATP1B1, and OATP1B3 (N = 28); and inducers of CYP3A and UGTs (N = 16). One drug was identified as a strong CYP3A inhibitor and one as a strong CYP3A inducer based on dedicated DDI studies with midazolam. No sensitive substrates were identified. No drugs related to renal transporters were identified in this update.
In addition, a comprehensive review of UGT-related data curated in DIDB resulted in the characterization of 3 drugs as UGT substrates, 11 as UGT inhibitors, and 13 as UGT inducers, supported by DDI or pharmacogenetic data.
You may access the Navigator to view the full list of compounds, along with supporting study details and additional pharmacokinetic information.
As always, feel free to contact us if you have any questions or comments.